Precigen, Inc. (PGEN) 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Precigen, Inc.
Reporting Period: Fiscal Year Ended December 31, 2024
Business Overview: Precigen is a clinical-stage biopharmaceutical company focused on gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company operates two reportable segments: Biopharmaceuticals (clinical drug development) and Exemplar (research models and services).
Strategic Shift: In August 2024, the company announced a strategic prioritization to focus resources on its lead program, PRGN-2012 (zopapogene imadenovec), for the treatment of Recurrent Respiratory Papillomatosis (RRP). This involved pausing enrollment in UltraCAR-T trials (PRGN-3005, PRGN-3007) and shutting down the ActoBio subsidiary operations.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $3.9 million | $6.2 million | (36.9%) |
| Net Loss | $(126.2) million | $(95.9) million | (31.6%) |
| Operating Loss | $(135.0) million | $(99.8) million | (35.4%) |
| Research & Development Expenses | $53.1 million | $48.6 million | +9.2% |
| Cash & Cash Equivalents | $29.5 million | $7.6 million | N/A |
| Total Investments (Short & Long Term) | $68.4 million | $55.3 million | N/A |
| Accumulated Deficit | $(2.09) billion | $(1.96) billion | N/A |
Liquidity: As of December 31, 2024, the company held approximately $97.9 million in cash, cash equivalents, and short-term investments. In December 2024, the company raised approximately $78.5 million through the issuance of Series A Preferred Stock and Warrants, and $30.9 million in August 2024 via a common stock offering.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 36.9% primarily due to a 100% drop in collaboration/licensing revenue (termination of the Alaunos agreement) and a 36.6% decline in Exemplar product and service revenues.
- Impairment Charges: The company recorded significant non-cash impairment charges totaling approximately $40.3 million. This includes $7.4 million in goodwill impairment (ActoBio and Exemplar) and $32.9 million in impairment of other noncurrent assets (primarily ActoBio developed technologies and long-lived assets).
- Restructuring Costs: The company incurred approximately $2.1 million in severance and termination benefits related to the shutdown of ActoBio and a workforce reduction of over 20% to support the strategic pivot to PRGN-2012.
- Other Income: Total other income increased 106.2% to $7.0 million, driven by an $8.5 million gain on the sale of intellectual property rights related to FCX-007.
Guidance, Outlook, and Risks
Regulatory Milestone: The FDA has accepted the Biologics License Application (BLA) for PRGN-2012 and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date is set for August 27, 2025.
Going Concern Warning: The company has identified conditions that raise substantial doubt about its ability to continue as a going concern. Management's ability to fund operations for the next 12 months is dependent on the successful FDA approval and commercialization of PRGN-2012, which is outside the company's direct control. The financial statements do not include adjustments that might result if the company cannot continue as a going concern.
Key Risks:
- Capital Needs: The company requires substantial additional capital. It has limited authorized shares available for future issuance, which could hinder equity fundraising without shareholder approval.
- Regulatory Uncertainty: Failure to obtain FDA approval for PRGN-2012 would prevent commercialization and likely lead to insolvency.
- Stock Listing: The company previously received a deficiency letter from Nasdaq regarding the minimum bid price requirement but regained compliance in January 2025. Continued compliance is not guaranteed.
- Warrant Liability: The company recorded a $50.5 million warrant liability associated with the December 2024 financing, which is subject to fair value remeasurement and could impact future earnings.
Investor Verification Checklist
- BLA Status: Verify the status of the PRGN-2012 BLA review and any potential delays to the August 27, 2025 PDUFA date.
- Cash Runway: Assess the burn rate against the $97.9 million cash position to determine the likelihood of needing additional dilutive financing before PRGN-2012 approval.
- Authorized Shares: Monitor shareholder votes regarding the increase in authorized common stock, which is a condition for the conversion of Series A Preferred Stock and exercise of Warrants.
- Warrant Liability Volatility: Review future quarterly reports for fluctuations in the $50.5 million warrant liability, which could create significant non-cash volatility in net income.
- Exemplar Segment: Evaluate the sustainability of the Exemplar segment, which continues to generate revenue but recorded a goodwill impairment in 2024.